146 related articles for article (PubMed ID: 28341412)
1. Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma.
Otemuyiwa B; Derstine BA; Zhang P; Wong SL; Sabel MS; Redman BG; Wang SC; Alva AS; Davenport MS
Acad Radiol; 2017 Sep; 24(9):1094-1100. PubMed ID: 28341412
[TBL] [Abstract][Full Text] [Related]
2. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
3. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
4. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
[TBL] [Abstract][Full Text] [Related]
5. Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.
Kwon WA; Cho IC; Yu A; Nam BH; Joung JY; Seo HK; Lee KH; Chung J
Ann Surg Oncol; 2013 Dec; 20(13):4397-404. PubMed ID: 24081805
[TBL] [Abstract][Full Text] [Related]
6. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu K; Koga F
J Urol; 2016 Jan; 195(1):26-32. PubMed ID: 26292042
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy.
Kwon WA; Kim S; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Clin Genitourin Cancer; 2017 Feb; 15(1):100-111. PubMed ID: 27601363
[TBL] [Abstract][Full Text] [Related]
10. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
11. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
12. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Klapper JA; Downey SG; Smith FO; Yang JC; Hughes MS; Kammula US; Sherry RM; Royal RE; Steinberg SM; Rosenberg S
Cancer; 2008 Jul; 113(2):293-301. PubMed ID: 18457330
[TBL] [Abstract][Full Text] [Related]
13. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
14. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
15. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
17. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
[TBL] [Abstract][Full Text] [Related]
20. CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men with Prostate Cancer.
McDonald AM; Swain TA; Mayhew DL; Cardan RA; Baker CB; Harris DM; Yang ES; Fiveash JB
Radiology; 2017 Feb; 282(2):475-483. PubMed ID: 27598538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
